IDEX (IEX) Stock Forecast & Price Target

IDEX is well positioned by its pivot toward higher-growth end markets, especially HST exposures to data centers, semiconductors, space and defense, pharma, and water, which drove 2Q26 organic orders up 28% year over year and lifted the book-to-bill to 1.16x. The company’s 2026 outlook improved to 5%-6% organic growth and adjusted EPS of $8.70-$8.85, supported by productivity gains, tariff-refund benefits, and stronger operating margins, while 2Q26 free cash flow converted at 103% of net income and net leverage stayed modest at 1.3x. Its disciplined 80/20 operating model, improving contributions from acquisitions, and active capital deployment through buybacks and bolt-on M&A provide a durable path for margin expansion and earnings growth into 2027.

IDEX is viewed negatively because its short-cycle, order-booked model leaves limited visibility, while tariff and trade pressures, currency volatility, and public funding or government spending cutbacks could all weigh on volumes and margins across industrial, municipal, and health and science end markets. The risk profile is heightened by the possibility of a prolonged inventory reset in higher-margin businesses and weaker demand in key growth platforms, which could trigger volume deleverage even as the company generates about $3.5 billion in revenue in 2025. Although shares trade at 22.4x 2027 P/E and 17.4x 2026E EV/EBITDA, the valuation only looks modestly cheaper than peers, leaving limited cushion if execution falters or short-cycle choppiness persists.